Live Breaking News & Updates on New Therapeutic Agents

Stay updated with breaking news from New therapeutic agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 Data presented at European Atherosclerosis Society 92nd Congress and ....

Vince Anzalone , Robert Rosenson , Brian Ritchie , Coll Cardiol , Kendy Guarinoni , Gugliucciaj Clin , Lifesci Advisors , Arrowhead Pharmaceuticals Inc , European Atherosclerosis Society , Exchange Commission , Lifesci Communications , Icahn School Of Medicine At Mount Sinai , Arrowhead Pharmaceuticals , New England Journal , Bruce Given , Icahn School , Mount Sinai , Principal Investigator , Atherosclerosis Society , Congress May , Late Breaker Session , New Therapeutic Agents , Harbor Statement , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports ,

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol

- Data presented at European Atherosclerosis Society 92nd Congress. ....

Daniel Gaudet , Coll Cardiol , Gugliucciaj Clin , Robert Rosenson , Christiem Ballantyne , Baylor College Of Medicine , Arrowhead Pharmaceuticals Inc , Exchange Commission , European Atherosclerosis Society , Arrowhead Pharmaceuticals , European Medicines Agency , Drug Administration , New England Journal , Baylor College , Principal Investigator , Atherosclerosis Society , New Therapeutics , Saag Session , Late Breaker Session , New Therapeutic Agents , Orphan Drug Designation , Fast Track Designation , European Medicines , Harbor Statement , Private Securities Litigation Reform Act , Annual Report ,